Alzinova (OM:ALZ) - Stock Price, News & Analysis

ALZ Stock Overview

Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer’s disease in Sweden.

About the company

ALZ fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Risk Analysis

Earnings are forecast to decline by an average of 57.5% per year for the next 3 years

Shareholders have been diluted in the past year

Does not have meaningful revenue (SEK20M)

Alzinova AB (publ) Competitors

Sprint Bioscience

OM:SPRINT

kr90.6m

Spago Nanomedical

OM:SPAGO

kr80.4m

CombiGene

OM:COMBI

kr75.2m

Abera Bioscience

NGM:ABERA

kr72.8m

Price History & Performance

Summary of all time highs, changes and price drops for Alzinova
Historical stock prices
Current Share Price	kr1.70
52 Week High	kr3.92
52 Week Low	kr1.67
Beta	0.99
1 Month Change	-10.53%
3 Month Change	-34.49%
1 Year Change	-33.33%
3 Year Change	-78.15%
5 Year Change	-88.67%
Change since IPO	-87.22%

Recent updates

Shareholder Returns

	ALZ	SE Biotechs	SE Market
7D	-2.9%	2.5%	-0.7%
1Y	-33.3%	-3.4%	4.4%

Price Volatility

Is ALZ's price volatile compared to industry and market?
ALZ volatility
ALZ Average Weekly Movement	7.7%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.1%
10% most volatile stocks in SE Market	13.1%
10% least volatile stocks in SE Market	3.5%

About the Company

Founded	Employees	CEO	Website
2011	4	Kristina Torfgard	www.alzinova.com

Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer’s disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer’s disease; and ALZ-201, a monoclonal antibody that neutralizes the toxic oligomers. The company was founded in 2011 and is based in Mölndal, Sweden.

Alzinova AB (publ) Fundamentals Summary

How do Alzinova's earnings and revenue compare to its market cap?
ALZ fundamental statistics
Market cap	kr75.70m
Earnings (TTM)	-kr16.48m
Revenue (TTM)	kr19.87m

3.8x

P/S Ratio

-4.6x

P/E Ratio

Is ALZ overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALZ income statement (TTM)
Revenue	kr19.87m
Cost of Revenue	kr0
Gross Profit	kr19.87m
Other Expenses	kr36.35m
Earnings	-kr16.48m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 07, 2024

Earnings per share (EPS)	-0.37
Gross Margin	100.00%
Net Profit Margin	-82.92%
Debt/Equity Ratio	0.7%

How did ALZ perform over the long term?

See historical performance and comparison

ALZ Stock Overview

Rewards

Risk Analysis

Alzinova AB (publ) Competitors

OM:SPRINT

kr90.6m

OM:SPAGO

kr80.4m

OM:COMBI

kr75.2m

NGM:ABERA

kr72.8m

Price History & Performance

Recent News & Updates

Kristina Torfgård Leaves the CEO Position At Alzinova Ab, Effective July 31, 2024

Alzinova AB (Publ) Announces All Patients in the Extension Part of the Phase 1B Study Have Received Their Last Dose of ALZ-101

Alzinova AB (publ) Announces CFO Changes

Full year 2023 earnings released: kr0.37 loss per share (vs kr0.54 loss in FY 2022)

New major risk - Revenue and earnings growth

Alzinova AB (Publ) Receives Regulatory Approval to Evaluate A Higher Dose of the Vaccine Candidate Alz-101 in the Ongoing Phase 1B Study

Recent updates

Kristina Torfgård Leaves the CEO Position At Alzinova Ab, Effective July 31, 2024

Alzinova AB (Publ) Announces All Patients in the Extension Part of the Phase 1B Study Have Received Their Last Dose of ALZ-101

Alzinova AB (publ) Announces CFO Changes

Full year 2023 earnings released: kr0.37 loss per share (vs kr0.54 loss in FY 2022)

New major risk - Revenue and earnings growth

Alzinova AB (Publ) Receives Regulatory Approval to Evaluate A Higher Dose of the Vaccine Candidate Alz-101 in the Ongoing Phase 1B Study

Alzinova AB (publ) to Report Fiscal Year 2024 Results on Feb 27, 2025

New major risk - Market cap size

Alzinova AB Announces Primary Analysis Confirms Positive Phase 1B Results with ALZ-101 against Alzheimer's

Alzinova AB (publ), Annual General Meeting, May 29, 2024

Alzinova AB (Publ) Announces Retiremet of Håkan Skogström as CFO

Alzinova AB (publ) Announces Positive Phase 1b Results with the Vaccine Candidate ALZ-101 Against Alzheimer's Disease

Third quarter 2023 earnings released

New minor risk - Share price stability

New major risk - Market cap size

Alzinova AB (publ) Receives Positive Response from the European Medicines Agency EMA

Second quarter 2023 earnings released

Alzinova AB (Publ) Appoints Kirsten Harting as New Chief Medical Officer, Effective from August 14, 2023

Alzinova AB (publ) Submits Request for Pre-IND Meeting with FDA and Applies for EMA Scientific Advice

Alzinova AB (Publ) Elects Julian Aleksov as Board Member and Chairman of the Board of Directors

First quarter 2023 earnings released

Director exercised options to buy kr8.7m worth of stock.

Chief Executive Officer exercised options to buy kr66k worth of stock.

Full year 2022 earnings released: kr0.40 loss per share (vs kr0.48 loss in FY 2021)

Alzinova AB (publ) Appoints Sebastian Hansson as the New Business Development Director

Alzinova AB (publ) Announces New Positive Safety Review and Interim Data from Ongoing Phase 1B Study with Vaccine Candidate ALZ-101

Alzinova AB (publ) Presents Data for its Preclinical Antibody Candidate ALZ-201 at Annual Alzheimer's Conference CTAD, Clinical Trials in Alzheimer's Disease

Alzinova AB (publ) to Report Fiscal Year 2023 Results on Feb 28, 2024

Less than half of directors are independent

Third quarter 2022 earnings released

Alzinova AB (publ) to Report Fiscal Year 2022 Results on Feb 23, 2023

Alzinova AB (Publ) Announces New Positive Safety Review of Its Phase 1B Study in Alzheimer's Disease

Second quarter 2022 earnings released

Alzinova AB (publ) Recruits Half of Patients for the Ongoing Phase 1B Study of the Vaccine Candidate ALZ-101

Alzinova AB (publ) Establishes Scaled-Up Manufacturing Process for ALZ-101 Ahead of Phase 2

Alzinova AB (publ) Initiates Development of a Stable Cell Line to Prepare the Monoclonal Antibody ALZ-201 for Alzheimer's Clinical Trials

Alzinova AB (publ) Initiates Development of a Stable Cell Line to Prepare the Monoclonal Antibody ALZ-201 for Alzheimer's Clinical Trials

Less than half of directors are independent

Full year 2021 earnings released: kr0.48 loss per share (vs kr0.41 loss in FY 2020)

Alzinova Improves Manufacturing Process of ALZ-101 to Meet Phase 2 Requirements

Full year 2021 earnings: EPS misses analyst expectations

Alzinova AB to Report Fiscal Year 2021 Results on Apr 14, 2022

Alzinova AB (publ) Completes Humanisation Work and Selects Lead Candidate for Monoclonal Antibody ALZ-201

Third quarter 2021 earnings released

Second quarter 2021 earnings released

First quarter 2021 earnings released

Full year 2020 earnings released: kr0.85 loss per share (vs kr0.81 loss in FY 2019)

Alzinova AB to Report Q3, 2021 Results on Oct 28, 2021

Alzinov AB Announces Drug Substance for the ALZ-101 Vaccine is Now Produced

New 90-day low: kr6.94

New 90-day low: kr7.30

Alzinova AB Announces the Study Design for the First Clinical Study with the Oligomer-Specific Therapeutic Vaccine ALZ-101 at a Scientific Congress

Third quarter earnings released

Alzinova AB (publ) Receives Positive Feedback from the Finnish Medicines Agency Fimea in View of the Upcoming Clinical Trial Application for the Alz-101 Alzheimer's Disease Vaccine

New 90-day low: kr8.68

New 90-day low - kr9.66

Earnings released

Shareholder Returns

Price Volatility